Stay updated on SEA-CD70 Safety in Myeloid Malignancies Clinical Trial
Sign up to get notified when there's something new on the SEA-CD70 Safety in Myeloid Malignancies Clinical Trial page.

Latest updates to the SEA-CD70 Safety in Myeloid Malignancies Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check16 days agoChange DetectedThe date has been updated from March 11, 2025, to April 16, 2025.SummaryDifference0.7%
- Check23 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 11, 2025. However, there are no significant changes to core content, pricing, or availability.SummaryDifference0.7%
- Check52 days agoChange DetectedThe date has been updated from March 7, 2025, to March 11, 2025.SummaryDifference0.3%
- Check59 days agoChange DetectedThe page has updated the reference to Seagen, clarifying its relationship as a subsidiary of Pfizer, and has changed the date from October 9, 2024, to March 7, 2025.SummaryDifference3%
Stay in the know with updates to SEA-CD70 Safety in Myeloid Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SEA-CD70 Safety in Myeloid Malignancies Clinical Trial page.